Can Suppressing a Protein Associated With Good Health Help Treat MS?

Gladstone Institutes scientists have discoveredĀ a successful new treatment that could potentially be used in multiple sclerosis (MS). The treatment involves suppressing a protein that traditionally is associated with overall good health. The study,Ā SIRT1 Deacetylates RORĪ³t and Enhances Th17 Cell Generation, appeared April 27, 2015 in theĀ Journal…

MS Views and News to Host Educational Patient Programs in May

MS Views and News (MSVN), aĀ non-profit organization focused on collecting and distributing information aboutĀ multiple sclerosis (MS), is hosting a series of educational patient programs and events during the month of May. The events have different themes,Ā but are all focused on the management of MS, includingĀ medication, avoiding…

FDA Accepts Bayerā€™s BETACONNECT License Application for Relapsing-Remitting Multiple Sclerosis

Bayer HealthCareĀ recently announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a supplemental Biologics License Application (sBLA) for BETACONNECT forĀ the treatment of relapsing-remitting multiple sclerosis (MS). BETACONNECT isĀ a new drug delivery option for patients under Bayerā€™s BETASERONĀ® (interferon beta-1b) therapy. MS is a…

Actelion to Accelerate Clinical Trials For Experimental Therapy That Treats MS, Other Autoimmune Diseases

Actelion Pharma recently announced that it will accelerate the launchĀ of clinical trials involving its lead drug candidateĀ ponesimod, an oral, selective sphingosine-1-phosphate (S1P1). This decision came after a group of scientists working on different phases of clinical trials for the therapy observedĀ mostly positive effects of ponesimod in terms of efficacy, efficiency…

Phase III Study of Experimental MS Therapy Meets Primary Endpoint, Results to be Presented at ANN Meeting

MedDay, a French biotechnology company that studies treatments for nervous system disorders, including multiple sclerosis, announced that MD1003, a highly-concentrated biotin, is effective forĀ treatment of progressive multiple sclerosis, according to results from a recent Phase III trial. MD1003 may have two beneficial effects: 1) increasing myelin, the fatty nerve-insulating…

CorTechs Labs And Novartis Partner On Solutions for Quantifying Brain Volume In MS Patients

San Diego based medical software developer CorTechs LabsĀ announced that it has entered into a partnership agreement with multinational pharmaceutical maker Novartis Pharma AG. The two companies will collaborate in further development of Cortechs’ powerful NeuroQuant breakthrough 510(k) cleared software brain volume quantification device that targets identification, measurement and tracking…

Biogen To Present Data On The Effectiveness of TECFIDERA In Newly-Diagnosed MS Patients During The ANN Annual Meeting

BiogenĀ hasĀ recently announced novelĀ results to support the effectiveness of TECFIDERAĀ (dimethyl fumarate) inĀ the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). The results revealed that TECFIDERA significantly reduced disability progression andĀ relapses in RRMS patients who received their diagnosis for the first time and had a highly active form of the disease.Ā TECFIDERA…

Two Already-Approved Medications Could Treat MS

Two already available medicationsĀ could be used to treatĀ multiple sclerosis (MS). In a newĀ study titled, “Drug Based Modulation of Endogenous Stem Cells,” published in the journal NatureĀ on April 20, 2015, scientists report that twoĀ drugs couldĀ activate stem cells in the brain, possibly repairing MS-induced damage to…

Two Researchers Investigate FACETS Program to Fight Fatigue in MS

Throughout the years, Dr. Sarah Thomas and Dr. Peter Thomas at Bournemouth University have been developing a program to aid multiple sclerosis patients affected by fatigue. Their program, developed at the Bournemouth University Clinical Research Unit in collaboration with colleagues at Dorset Multiple Sclerosis Service at Poole Hospital, is a…

Epilepsy Drug May Treat Eye Complications in Patients With MS

A new study to beĀ presented during the American Academy of Neurology’s 67th Annual Meeting, April 24, in Washington, DC, explores the use ofĀ phenytoin, a drug commonly used to treat epilepsy, as a novel treatment for acute optic neuritis, a severe eye complication of multiple sclerosis (MS) that affects approximately half…

Progressive MS Pipeline Slowly Filling With New, Experimental Therapies

As the most common non-traumatic cause of disability in young people in the industrialized world, multiple sclerosis affects more than 2.5 million people globally. Those who suffer with the diseaseĀ are categorized into two types of multiple sclerosis patients: those with relapsing-remitting multiple sclerosis (RRMS) make up the majority of patients…

PatientsLikeMe/Biogen Study Evaluates Wearable Devices To Monitors Activity Of People With MS

Cambridge, Massachusetts basedĀ PatientsLikeMe has released results of a novel study conducted in conjunction with pharmaceutical maker Biogen that demonstrated how people living with multiple sclerosis (MS) can employ wearable activity tracking devices to monitor, collect, and share their personal mobility data. That information can potentially be relevant for…

Case Study Highlights Demyelinating Lesion in Pediatric MS Patient Discovered After Abdominal Pain

Considering the range of neurological symptoms normally associated with adult multiple sclerosis (including loss of coordination, weakness, fatigue, and trouble thinking), symptoms of pediatric multiple sclerosis are often nonspecific and affect the intestinal system. Intestinal mobility and sensation, vomiting, and long transit time for digestion (dysphagia) are symptoms that also…

New Novartis Analyses On Gilenya For Relapsing Multiple Sclerosis To Be Presented at Upcoming Conference

NovartisĀ will present novelĀ GilenyaĀ data, demonstratingĀ the company’s methods for assessing the impact of relapsing multiple sclerosis (RMS) in bothĀ patients and physicians, during the 67th Annual Meeting of American Academy of Neurology (AAN) that will take place in Washington, DC between the 18th and the 25th of April, 2015. The data will…

Amarantus Advancing MSPrecise For Improved Diagnosis of Relapsing-Remitting MS

Amarantus BioScience Holdings, Inc. (Amarantus) is a San Francisco based, development-stage, publicly-traded biotechnology company focused on discovering and developing first-in-class treatments and diagnostics in neurology for diseases associated with the dysfunction of a wide range of biological pathways, including protein misfolding, cell cycle dysregulation, neurodegeneration and apoptosis (Programmed Cell…

Biogen to Focus on RRMS Disease Management, Treatment at Upcoming Conference

Biogen plans toĀ present new clinical data at the 67th American Academy of Neurology (AAN) Annual Meeting in Washington D.C., April 18 ā€“ 25, 2015, including numerous presentations focusing on multiple sclerosis. Ā In a company press release, Biogen statedĀ ā€œAt AAN, we will feature new scientific data, including research highlighting the…